Netflix's 'The Bleeding Edge' Isn't Even Out Yet and Essure Has Already Been Pulled

(Image credit: Netflix, Bayer)

published 24 July 2018

Years after the first reports of hazardous effects of birth control device Essure—and days before a Netflix documentary about it drops—manufacturer Bayer announced it will stop selling the controversial implant. The company framed its decision as based on poor sales, but the timing is hard to ignore: The Bleeding Edge, a documentary about medical devices gone awry that uses Essure as a prime example, drops on July 27. Essure was pulled July 20.

"We continue to stand behind the product's safety and efficacy," Bayer said in a statement. The company has maintained for years that Essure, a kind of metal coil that is implanted in the Fallopian tubes to block sperm, is safe, despite facing roughly 16,000 lawsuits from women who say they suffered ill effects after using it, including organ perforation, chronic and excessive pain, and unintended pregnancies. Yet Essure was discontinued due to a "business decision," the company said, citing "a decline in sales."

Meanwhile, Friday marks the launch of The Bleeding Edge, a Netflix documentary from the creators of The Hunting Ground. The Hollywood Reporter describes it as "a terrifying eye-opener," and Indiewire writes that it "stands a good chance at enlightening more people who have been (or might be) hoodwinked." The documentary isn't just about Essure—it focuses on a handful of medical devices that have caused major complications, including "vagical mesh" and hip replacements—but Essure is framed as a banner example of good intentions gone haywire.

The Bleeding Edge | Trailer [HD] | Netflix - YouTube

Watch On

When it comes to Essure, Bayer has suffered a particularly nasty year. Essure has been pulled or withdrawn from every country where it had been offered outside of the United States—Canada, the U.K., the Netherlands, you name it—and in April, the FDA announced it would be restricting sales of Essure to ensure that all women who consider it are fully aware of the risks. (Restricting sales, in this case, means only selling the device to facilities that agreed to review a set checklist with doctors and patients.) That said: "The FDA continues to believe that the benefits of the device outweigh its risks," the statement noted.

Once billed as the only permanent contraceptive device on the market, Essure has since become a buzzword for unexpected complications. On Facebook and other social media sites, there exists a growing community of Essure-affected women who congregate to share their experiences. Between 2002 and 2017, close to 30,000 women filed formal reports of "adverse effects" with the FDA after using Essure.

You can stream The Bleeding Edge on Netflix from July 27.

TOPICS

Jenny is the Digital Director at Marie Claire. A graduate of Leeds University, and a native of London, she moved to New York in 2012 to attend the Columbia University Graduate School of Journalism. She was the first intern at Bustle when it launched in 2013 and spent five years building out its news and politics department. In 2018 she joined Marie Claire, where she held the roles of Deputy Digital Editor and Director of Content Strategy before becoming Digital Director. Working closely with Marie Claire's exceptional editorial, audience, commercial, and e-commerce teams, Jenny oversees the brand's digital arm, with an emphasis on driving readership. When she isn't editing or knee-deep in Google Analytics, you can find Jenny writing about television, celebrities, her lifelong hate of umbrellas, or (most likely) her dog, Captain. In her spare time, she writes fiction: her first novel, the thriller EVERYONE WHO CAN FORGIVE ME IS DEAD, was published with Minotaur Books (UK) and Little, Brown (US) in February 2024 and became a USA Today bestseller. She has also written extensively about developmental coordination disorder, or dyspraxia , which she was diagnosed with when she was nine.

Stay In The Know